Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece

Figure 2

Progression-free (a) and overall survival (b) of patients receiving second-line chemotherapy according to the chemotherapy regimen. CAPOX, oxaliplatin/capecitabine; CAPOXIRI, oxaliplatin/irinotecan/capecitabine; FOLFOX, oxaliplatin/leucovorin/5-fluorouracil; FOLFIRINOX, oxaliplatin/irinotecan/leucovorin/5-fluorouracil.

(a)

(b)